RareResearch.AI
← Back to atlas

E202G

Category 4 — Stable Fold, Function DisruptedPathogenic/Likely pathogenicCytoplasmic · predictedEditorial
GlutamateGlycine at position 202 · N-terminal cytoplasmic domain (87-313) · WFS1 (Wolframin)

Glutamate-to-glycine substitution in wolframin's N-terminal cytoplasmic ATP6V1A-interaction region — a low AlphaMissense score (0.283, Likely Benign) sits in tension with the ClinVar Pathogenic/Likely pathogenic classification, requiring careful interpretation.

Interactive 3D Structure

Wild-type reference
Wild-type E202 — hydrogen bond to A198
Fullscreen ↗
DynaMut2 mutant · E202G
Mutant G202 — energy-minimized; local contact network preserved
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost0 gained4 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondA198A198Preserved
Polar contactA198A198Preserved
Polar contactE199E199Preserved
Polar contactV204V204Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.19kcal/mol
Destabilising — mild
AlphaMissense
0.283
LBen
AlphaFold pLDDT
74
model confidence
Schema
Cat 4
Category 4 — Stable Fold, Function Disrupted
ΔΔG confidence: Standard confidence · Cytoplasmic

This variant is in a water-facing region, which is the regime the stability predictor was built and benchmarked for. Ordinary predictor error still applies.

Clinical Evidence

ClinVar classificationPathogenic/Likely pathogenic
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsWolfram syndrome 1; Optic atrophy
InheritanceInheritance pattern not explicitly recorded.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0044%
cDNA changec.605A>G
ClinVar accessionVCV000420050
Last evaluated2024/06/04 00:00

Observed at very low frequency in gnomAD.

Classified for2★ documented assertion

ClinVar classifies this variant as Pathogenic/Likely pathogenic for Optic atrophy / optic neuropathy (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.

  • Optic atrophy / optic neuropathyautosomal dominantsubmitted as: Optic atrophy
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 2★ multiple submitters, no conflicts. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.0044% · 64 / 1,460,956 alleles
Homozygotes
0
Highest-frequency population
European (non-Finnish) · AF 0.0056%

Highest in European (non-Finnish): AF 0.0056% (62 of 1,112,004 alleles), in line with the global figure.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
European (non-Finnish)0.0056%62 / 1,112,0040~1 in 8970
Remaining individuals0.0033%2 / 60,3900~1 in 15100

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

E202 is held between Asn203 (2.46 Angstrom) and Leu201 (2.46 Angstrom) covalently, with through-space contacts to Ala198 (3.93 Angstrom), Glu199 (3.96 Angstrom), Val204 (4.36 Angstrom), and Leu200 (4.57 Angstrom). The local environment is mixed polar-aliphatic: two leucines, an alanine, a valine, an asparagine, and another glutamate (E199) within 4.5 Angstrom. The Glu199-Glu202 pair is interesting — two negatively charged carboxylates within 4 Angstrom likely participate in a coordinated electrostatic feature, either repelling each other to maintain extended conformation or both coordinating a divalent metal cation or a positively charged binding partner.

The E202G substitution removes the side chain entirely. Glycine introduces backbone freedom where the wild-type maintained a side-chain-rigidified conformation. The Glu199-Glu202 coordinated electrostatic feature is destroyed — only Glu199 remains. If the wild-type pair coordinated a cation or formed part of an ATP6V1A-binding salt-bridge interface, that functionality is now lost.

DynaMut2 reports DeltaDeltaG = -0.19 kcal/mol — essentially unchanged. AlphaMissense, however, scores E202G at 0.283 (Likely Benign by the AM classifier). This is a notable discordance with ClinVar's Pathogenic/Likely pathogenic classification. Three possible reconciliations: (a) the AM model under-weighs charge-removal mutations in surface-exposed regions; (b) ClinVar evidence for E202G derives from a small number of affected families and may include linkage to a separate causal variant; (c) the variant is genuinely a partial loss-of-function with subtle cellular consequences that AM does not detect.

The structural signature — a Glu pair at the ATP6V1A-binding interface, broken by removal of one Glu — is functionally plausible. The Atlas should flag E202G as a discordant-metric variant requiring careful clinical follow-up rather than confident druggability assignment.

Amino-acid chemistry
Glutamate (negatively charged carboxylate side chain) to Glycine (no side chain at all — backbone-only residue with unique torsional freedom) at position 202. The substitution removes both a charge and a side-chain heavy atom, replacing them with backbone flexibility.
Position in the protein
Position 202 sits inside wolframin's N-terminal cytoplasmic domain (residues 87-313), within the UniProt-annotated Region of interaction with ATP6V1A (residues 1-321). pLDDT 74.12 places E202 in a confidently modeled region.

Druggability Assessment

Final classification: Category 4 — Stable Fold, Function Disrupted, with metric-discordance caveat. The DeltaDeltaG magnitude (0.19 kcal/mol) is small; the pLDDT (74.12) is good; the AlphaMissense score (0.283) is unusually low for a ClinVar-pathogenic variant. The structural-chemistry case for a functional-site disruption (loss of the Glu199-Glu202 electrostatic feature on the ATP6V1A-binding surface) is suggestive but not conclusive. For druggability, the metric discordance argues for clinical follow-up before therapeutic investment. If the ClinVar evidence is solid, the lesion is on a binding surface and is small-molecule-accessible. If the AlphaMissense score is reading the biology correctly, the variant may not require dedicated therapeutic effort. The recommendation is to validate the clinical phenotype attribution before launching a chaperone screen.

Why this matters

E202G is the Atlas's first cleanly-discordant case in this batch — ClinVar Pathogenic but AlphaMissense Likely Benign. These discordances are exactly the variants the Atlas should surface for human review, not paper over. The schema does not force a confident druggability call when the underlying metrics disagree. The broader lesson is that the Atlas's value comes partly from honest flagging of cases where the available evidence is internally inconsistent. A real-world variant database will contain many such cases, and the right Atlas behavior is to report the discordance, frame the most plausible interpretation, and direct the clinical user to the specific data points that resolve the ambiguity. E202G is a teachable example for how the Atlas handles metric tension.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the E202G PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download E202G PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Region1321 · Interaction with ATP6V1A